The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.

This treatment has been approved for sale to the public.

Study NCT00354627 Information provided by Tibotec Pharmaceuticals, Ireland

First Received: July 18, 2006 Last Updated: November 25, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This treatment has been approved for sale to the public.
Estimated Study Completion Date:	December 2011
Estimated Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)